AIM To describe the clinical characteristics and the care pathways of patients with multiple myeloma (MM) benefiting from hospital at home (HAH) for their parenteral anticancer treatment METHOD A retrospective scheme conducted in HAH of Assistance-Publique des Hôpitaux de Paris (APHP). All patients starting bortezomib treatment line in HAH were included in 2015. Data collection was based on CHIMIO® software and on medical records. We analyzed the patient’s characteristics, their pathways, their long-term outcomes. RESULTS Of 536 patients treated for cancer in HAH, 154 patients received bortezomib. 73,4% patients began their first line for their symptomatic MM. Mean age was 70,6 years, 27,3 % under 65 years, 53,9% of men, 27,3% living alone, a median Karnofsky Performans Status of 70. One third of elderly lived alone, 16,1% required domestic help. The median number of courses was 6 (range: 1-14), the mean duration of treatment was 6,6 m (+ 3,5) in HAH. The median time to next treatment was 17,5 (range:0-50) months. After 24 months of follow-up after the first administration in HAH, 77,9% were alive. The median overall survival was still not reached at 4 years. 58,8% -mainly the youngest- went back to HAH for the subsequent treatment. CONCLUSION Patients treated in HAH for MM - regardless of age and therapeutic goal- were mainly independent, treated from the first line in a radius close to hospital. The involvement of HAH was achieved without safety issues nor compromised long-term outcomes. This study described the real-world patterns of patients benefiting from HAH.